Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX/TEZ/IVA effects on glucose tolerance in cystic fibrosis with abnormal glucose metabolism
NL-OMON52358Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change from baseline in 2-hour blood glucose after oral glucose tolerance test. Started Mar 2021; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON52358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52358.